Beyond appetite suppression, GLP-1 RAs improve systemic glucose homeostasis through pancreatic and extra-pancreatic mechanisms
This combination is utilized to support weight loss efforts
Findings presented at the SCAI 2026 Scientific Sessions & CAIC-ACCI Summit in Montreal in April indicate that GLP-1 medications containing tirzepatide (Mounjaro and Zepbound) may help lower the risk of heart problems in people with obesity undergoing certain heart procedures
It is widely studied for its potential in tissue repair, inflammation reduction, and accelerated healing of muscles, tendons, ligaments, and the gastrointestinal tract
- when there is risk of torsades de pointes, for example in patients with prolonged QT, concomitant administration of other medications that produce torsades de pointes (amiodarone, quinidine, bepridil, IV erythromycin, halofrantine, pentamidine, sparfloxacin, sultopride, vincamine, betrilio, disopyramide, sotalol, etc)